Geoff Oxnard
Vermogen: 331 512 $ op 30-09-2026
Vermogen: 331 512 $ op 30-09-2026
Geoff Oxnard is Chief Medical Officer & Executive Vice President at Blossomhill Therapeutics, Inc. since 2025.
Formerly, Dr. Oxnard was Vice President & Global Head-Thoracic Cancers at Eli Lilly & Co. from 2023 to 2025 and Senior Vice President & Head-Clinical Development at F.
Hoffmann-La Roche Ltd. from 2021 to 2023.
Education includes undergraduate studies at Harvard University and a doctorate from Pritzker School of Medicine.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 07-08-2026 | 17.785 ( 0,06% ) | 331 512 $ | 30-09-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| BLOSSOMHILL THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-01-2025 |
| Bedrijven | Functie | Einde |
|---|---|---|
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 01-01-2025 |
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Corporate Officer/Principal | 01-09-2023 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 5 |
|---|---|
Eli Lilly & Co.
Eli Lilly & Co. Pharmaceuticals: MajorHealth Technology Manufactures, wholesales and markets pharmaceutical products | Health Technology |
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Harvard University
Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pritzker School of Medicine
Pritzker School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Blossomhill Therapeutics, Inc.
Blossomhill Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops therapeutics for oncology and autoimmune diseases | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau